Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2020000461) METHOD FOR TARGETED KNOCKOUT OF HUMAN NARC1 GENE WITH CRISPR/CAS9 AND SPECIFIC GRNA THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2020/000461 International Application No.: PCT/CN2018/093871
Publication Date: 02.01.2020 International Filing Date: 29.06.2018
IPC:
C12N 15/113 (2010.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants:
深圳市博奥康生物科技有限公司 SHENZHEN BIOCAN TECHNOLOGIES CO., LTD. [CN/CN]; 中国广东省深圳市 南山区西丽街道珠光路134号珠光创新科技园1栋509室 毛吉炎 MAO, Jiyan Room 509, Building 1, Zhuguang Innovation Park No.134 Zhuguang Road, Xilii Street, Nanshan District Shenzhen, Guangdong 518055, CN
Inventors:
毛吉炎 MAO, Jiyan; CN
Priority Data:
Title (EN) METHOD FOR TARGETED KNOCKOUT OF HUMAN NARC1 GENE WITH CRISPR/CAS9 AND SPECIFIC GRNA THEREOF
(FR) MÉTHODE POUR L'INACTIVATION CIBLÉE DU GÈNE NARC1 HUMAIN AVEC CRISPR/CAS9 ET ARNG SPÉCIFIQUE ASSOCIÉ
(ZH) CRISPR/Cas9 靶向敲除人 NARC1 基因的方法及其特异性 gRNA
Abstract:
(EN) Provided are a method for targeted knockout of the human NARC1 gene with CRISPR/Cas9 and the specific gRNA thereof. According to the design principle of CRISPR/Cas9, the method comprises: designing two target sites upstream and downstream of the human NARC1 gene; synthesizing corresponding oligonucleotide sequences and ligating same to px459 vector for the construction of a recombinant plasmid; transfecting the recombinant plasmid into a human esophageal cancer cell line for specifically knocking out the human NARC1 gene. The method can be applied to the clinical treatment of the human NARC1 gene-related diseases.
(FR) L'invention concerne une méthode d'inactivation ciblée du gène NARC1 humain avec CRISPR/Cas9 et son ARNg spécifique. Selon le principe de conception de CRISPR/Cas9, la méthode comprend : la conception de deux sites cibles en amont et en aval du gène NARC1 humain; la synthèse de séquences oligonucléotidiques correspondantes et la ligature de celles-ci à un vecteur px459 pour la construction d'un plasmide recombinant; la transfection du plasmide recombinant dans une lignée cellulaire du cancer œsophagien humain pour l'inactivation spécifique du gène NARC1 humain. La méthode peut être appliquée au traitement clinique des maladies associées au gène NARC1 humain.
(ZH) 提供了一种CRISPR/Cas9靶向敲除人NARC1基因的方法及其特异性gRNA。所述方法根据CRISPR/Cas9的设计原则,在人NARC1基因的上下游设计两个靶位点,合成相应的寡核苷酸序列,并连接至px459载体上构建重组质粒,将其转染人食管癌细胞株,能够特异性敲除人NARC1基因,可应用于人NARC1基因相关疾病的临床治疗。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)